Wellington Partners Venture Capital
Erich Schlick is one of a very few European scientists/drug developers to see their innovation become a blockbuster. This happened in the 1990s when he initiated the development of Humira, the first fully human therapeutic monoclonal antibody.
Erich joined Wellington in 2005 and works with portfolio companies Evolva, immatics, Oxagen, Sensimed, SuperSonic Imagine, and Symetis. Before Wellington, he served as Director and Head of 3i Healthcare Germany and as Deputy Sector Head 3i Healthcare Worldwide and was responsible for numerous successful investments.
Prior to venture capital, Erich spent 15 years with BASF Pharma Knoll AG, including 10 years as an executive board member with worldwide responsibility for preclinical and clinical R&D. During this time, he obtained worldwide registrations for five products in cardiovascular, metabolic and pain indications. In 1993, he established the partnership with Cambridge Antibody Technology (CAT), which led to the successful development of Humira.
Education, Personal, and Fellowship
Erich studied medicine in the universities of Berlin, Mainz and Heidelberg receiving an MD and a PhD degree in Pharmacology. He has gone on to be an external professor of pharmacology at the University of Heidelberg, teaching graduate courses in clinical pharmacology with a focus on Oncology/Immunology. Erich has also served as professor of Pharmacology at the University of Massachusetts.
Erich served his fellowship under mentor Rolf C. Dienst at Wellington Partners in Munich, Germany as a member of Fellows Class 9.